Live Chat ×
Skip to main content

Advances in bioavailability enhancing technologies for poorly soluble molecules: In vitro and In vivo case studies

Description

About this webinar

A number of solubility enhancing technologies are available to formulators to improve the bioavailability of poorly water-soluble molecules. The choice of a bioavailability enhancing technology can be rationally based on an understanding of the physical-chemical properties of the molecule augmented with in-vitro measurements to help define the mechanism that is limiting bioavailability. For example, the bioavailability of molecules with poor dissolution rates can be improved with straightforward solutions such as particle size reduction. Conversely, molecules that are poorly soluble due to high crystal forces or high lipophilicity can be improved by the use of amorphous solid dispersions (ASD) or lipid-based formulations (LBF), respectively. Commercial products have been developed using each of these technologies.

This presentation will discuss the fundamental formulation and processing considerations for obtaining a high-performing and physically- and chemically stable formulation without excessive formulation or process iteration. In addition, in vitro methodologies for choosing the most appropriate technology based on compound properties will be presented. For each of these formulation case studies, validation of the technology selection methods will be confirmed with animal in-vivo data.

Learning Objectives

  • Describe bioavailability enhancing (BAE) technologies
  • Identify In vitro methodologies for choosing BAE technologies
  • Discuss technology selection case studies
  • Examine In vivo validation of methodologies

Contributors

  • David Lyon, Ph.D.

    David Lyon received his B.S. in Chemistry from Western Washington University and Ph.D. in Inorganic Chemistry from the University of Oregon. Following a Post-Doctoral stint at the California Institute of Technology, David joined Bend Research as a Research Chemist. During his tenure at Bend Research he held positions of increasing responsibility culminating in the role of Senior Vice President, Research prior to the company’s acquisition by Capsugel and, subsequently, Lonza. He currently serves as a Sr. Fellow, Research advising internal and external collaborations in bioavailability enhancement technologies, modified release and bioprocessing. David has been involved in numerous technology innovation efforts during his career including the development of amorphous dispersions, modified release formulations, engineered particles for inhalation, nanotechnology and formulation and processing of biotherapeutics.

April 16, 2020
Thu 12:30 PM EDT

Duration 1H 30M

Register Already Registered?